Skip to main content
The Markets by Proactive
Go to Proactive UK
Proactive UK has moved. Proactive’s coverage of London’s small caps continues on proactiveinvestors.com Go there →
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Coverage of London’s small caps continues on proactiveinvestors.com
Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK

Pharma & Biotech

Psyence Group unveils GOODMIND line of functional mushroom products

The product line was designed to nourish the mind and elevate everyday life by enhancing mental capacity and the body’s ability to adapt to stress

Psyence Group Inc (CSE:PSYG) has introduced a premium range of functional mushroom products under the GOODMIND banner.

The international biotechnology company with operations in South Africa described the GOODMIND formula as harnessing the power of adaptogens; non-toxic, non-psychoactive fungi, used for centuries in traditional medicine for their stress-relieving benefits.

The product line was formulated to nourish the mind and elevate everyday life by enhancing mental capacity and the body’s ability to adapt to stress.

READ: Psyence Group teams up with Clerkenwell Health to study the effect of psychedelics in palliative care

GOODMIND falls in line with Psyence’s larger goal of helping patients heal from psychological trauma and its mental health consequences in the context of palliative care.

To bring the products to the South African marketplace, Psyence partnered with Goodleaf, a leading wellness and lifestyle brand specializing in CBD with a premium range of products infused with African botanicals.

“We are delighted that our first nutraceutical product, GOODMIND, is now available for sale online in South Africa. This is an important milestone for Psyence as we look to grow our over-the-counter nutraceutical wellness collection,” Neil Maresky, CEO at Psyence Group said in a statement.

“Goodleaf has a proven track record of successfully launching and distributing high-quality products and we believe they are an excellent partner to successfully launch GOODMIND in this growing market,” Maresky added.

Both companies intend to leverage their knowledge and experience in the nutraceutical and supplement industry to create class-leading products in the functional mushroom space.

“Our experience in developing and launching new consumer products will be invaluable as we make headway in the functional mushroom space,” said Warren Schewitz, founder and CEO of Goodleaf, who went on to note that there is a growing demand for wellness products.

To learn more about the products visit the GOODMIND website.

Contact the writer at georgia@proactiveinvestors.com

Follow her on Twitter @MissInformd

Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK